All Title Author
Keywords Abstract

PLOS ONE  2013 

Tamoxifen Ameliorates Peritoneal Membrane Damage by Blocking Mesothelial to Mesenchymal Transition in Peritoneal Dialysis

DOI: 10.1371/journal.pone.0061165

Full-Text   Cite this paper   Add to My Lib


Mesothelial-to-mesenchymal transition (MMT) is an auto-regulated physiological process of tissue repair that in uncontrolled conditions such as peritoneal dialysis (PD) can lead to peritoneal fibrosis. The maximum expression of peritoneal fibrosis induced by PD fluids and other peritoneal processes is the encapsulating peritoneal sclerosis (EPS) for which no specific treatment exists. Tamoxifen, a synthetic estrogen, has successfully been used to treat retroperitoneal fibrosis and EPS associated with PD. Hence, we used in vitro and animal model approaches to evaluate the efficacy of Tamoxifen to inhibit the MMT as a trigger of peritoneal fibrosis. In vitro studies were carried out using omentum-derived mesothelial cells (MCs) and effluent-derived MCs. Tamoxifen blocked the MMT induced by transforming growth factor (TGF)-β1, as it preserved the expression of E-cadherin and reduced the expression of mesenchymal-associated molecules such as snail, fibronectin, collagen-I, α-smooth muscle actin, and matrix metalloproteinse-2. Tamoxifen-treatment preserved the fibrinolytic capacity of MCs treated with TGF-β1 and decreased their migration capacity. Tamoxifen did not reverse the MMT of non-epitheliod MCs from effluents, but it reduced the expression of some mesenchymal molecules. In mice PD model, we demonstrated that MMT progressed in parallel with peritoneal membrane thickness. In addition, we observed that Tamoxifen significantly reduced peritoneal thickness, angiogenesis, invasion of the compact zone by mesenchymal MCs and improved peritoneal function. Tamoxifen also reduced the effluent levels of vascular endothelial growth factor and leptin. These results demonstrate that Tamoxifen is a therapeutic option to treat peritoneal fibrosis, and that its protective effect is mediated via modulation of the MMT process.


[1]  Margetts PJ, Bonniaud P (2003) Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 23: 530–541.
[2]  Krediet RT, Zweers MM, van der Wal AC, Struijk DG (2000) Neoangiogenesis in the peritoneal membrane. Perit Dial Int 20 (Suppl 2)S19–25.
[3]  Devuyst O, Margetts PJ, Topley N (2010) The Pathophysiology of the peritoneal membrane. J Am Soc Nephrol 21: 1077–1085.
[4]  Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, et al. (1996) Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory dialysis. A report of the Japanese sclerosing encapsulating peritonitis study group. Am J Kidney Dis 28: 420–427.
[5]  Ya?ez-Mo M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, et al. (2003) Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 348: 403–413.
[6]  Yang AH, Chen JY, Lin JK (2003) Myofibroblastic conversion of mesothelial cells. Kidney Int 63: 1530–1539.
[7]  Aguilera A, Ya?ez-Mo, Selgas R, Sánchez-Madrid F, López-Cabrera M (2005) Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs 6: 262–268.
[8]  Aroeira LS, Aguilera A, Sánchez-Tomero JA, Bajo MA, del Peso G, et al. (2007) Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 18: 2004–2013.
[9]  Selgas R, Bajo MA, Castro MJ, Sánchez-Tomero JS, Cirugeda A (2000) Managing ultrafiltration failure by peritoneal resting. Perit Dial Int 20: 595–597.
[10]  Kawanishi H (2005) The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis. Int J Artif Organs 28: 150–155.
[11]  Allaria PM, Giangrande A, Gandini E, Pisoni IB (1999) Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: Tamoxifen as a new therapeutic agent?. J Nephrol 12: 395–397.
[12]  Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, et al. (2009) The Pan-Thames EPS study: treatment and outcome of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 24: 3209–3215.
[13]  Park WC, Jordan VC (2002) Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 8: 82–88.
[14]  Clark CP, Vanderpool D, Preskitt JT (1991) The response of retroperitoneal fibrosis to Tamoxifen. Surgery 109: 502–506.
[15]  del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, et al. (2003) Clinical experience with Tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 19: 32–35.
[16]  Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, et al. (2011) Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 26: 691–697.
[17]  Huang JW, Yen CJ, Wu HY, Chiang CK, Cheng HT, et al. (2011) Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis. Blood Purif 31: 252–258.
[18]  Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, et al. (2010) Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Res Treat 123: 795–804.
[19]  Dellê H, Rocha JR, Cavaglieri RC, Vieira JM Jr, Malheiros DM, et al. (2012) Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol 23: 37–48.
[20]  Aroeira LS, Aguilera A, Selgas R, Ramírez-Huesca M, Pérez-Lozano ML, et al. (2005) Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 46: 938–948.
[21]  López-Cabrera M, Aguilera A, Aroeira LS, Ramírez-Huesca M, Pérez-Lozano ML, et al. (2006) Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. Perit Dial Int 26: 26–34.
[22]  Loureiro J, Aguilera A, Selgas R, Sandoval P, Albar-Vizcaíno P, et al. (2011) Blocking TGF-beta-1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol 22: 1682–1695.
[23]  Sandoval P, Loureiro J, González-Mateo G, Pérez-Lozano ML, Maldonado-Rodríguez, et al (2010) PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Lab Invest 90: 1517–1532.
[24]  Strippoli R, Benedicto I, Pérez Lozano ML, Cerezo A, López-Cabrera M, et al. (2008) Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappaB/Snail1 pathway. Dis Model Mech 1: 264–274.
[25]  Dhandapani K, Brann D (2003) Neuroprotective effects of estrogen and tamoxifen in vitro: a facilitative role for glia? Endocrine 21: 59–66.
[26]  Issandou M, Faucher C, Bayard F, Darbon JM (1990) Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res 50: 5845–5850.
[27]  Shao ZM, Radziszewski WJ, Barsky SH (2000) Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer lett 157: 133–144.
[28]  Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T (2002) Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 102: 188–194.
[29]  Hashimoto M, Inoue S, Muramatsu M, Masliah E (1997) Estrogens stimulate Tamoxifen-induced neuronal cell apoptosis in vitro: a possible nongenomic action. Biochem Biophys Res Commun 240: 464–470.
[30]  Mandlekar S, Kong AN (2001) Mechanisms of Tamoxifen-induced apoptosis. Apoptosis 6: 469–477.
[31]  Justo P, Lorz C, Sanz A, Egido J, Ortiz A (2003) Intracellular mechanisms of cyclosporin-A induced tubular cell apoptosis. J Am Soc Nephrol 14: 3072–3080.
[32]  Reckless J, Metcalfe JC, Grainger DJ (1997) Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 95: 1542–1548.
[33]  Sourla A, Luo S, Labrie C, Bélanger A, Labrie F (1997) Morphological changes induced by 6 month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology 138: 5605–5617.
[34]  Del Peso G, Jiménez-Heffernan JA, Bajo MA, Aroeira LS, Aguilera A, et al. (2008) Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int 108: S26–S33.
[35]  Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, et al. (2000) Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6: 4359–64.
[36]  Christodoulakos GE, Lambrinoudaki IV, Botsis DC (2006) The cardiovascular effects of selective estrogen receptor modulators. Ann N Y Acad Sci 1092: 374–384.
[37]  Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, et al. (2010) ER-alpha signaling through slug regulates E-cadherin and EMT. Oncogene 29: 1451–1462.
[38]  Yang AH, Huang SW, Chen JY, Lin JK, Chen CY (2007) Leptin augments myofibroblastic conversion and fibrogenic activity of human peritoneal mesothelial cells: a functional implication for peritoneal fibrosis. Nephrol Dial Transplant 22: 756–62.
[39]  Leung JCK, Chan LYY, Tang SCW, Chu KM, Lai KN (2006) Leptin induces TGF-β synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 69: 2078–2086.
[40]  Hozumi Y, Hakamata Y, Nagai H (2005) Plasma leptin concentration in Tamoxifen-treated ovariectomized rats. Gynecol Obstet Invest 59: 70–74.
[41]  Cakmak A, Posaci C, Dogan E, Caliskan S, Guclu S, et al. (2005) Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am J Obstet Gynecol 93: 347–351.
[42]  Guo K, McMinn JE, Ludwig T, Yu YH, Yang G, et al. (2007) Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. Endocrinol 148: 3987–3997.
[43]  Hausman GJ, Richardson RL (2004) Adipose tissue angiogenesis. J Anim Sci 82: 925–934.


comments powered by Disqus

Contact Us


微信:OALib Journal